Reduction of PrPC in human cerebrospinal fluid after spinal cord injury

Figures & data

Figure 1 PrP^C levels in human CS F are attenuated following spinal cord injury. (A) Western analysis of PrP^C in human CS F from control (lane1) and from spinal cord injured patient #19 (remaining lanes) at 12 h, 24 h, day 2, day 3, day 4, day 5 and day 6 following spinal cord injury. 40 µl of the indicated CS F samples were separated by SDS PAGE, the Western blot was probed with anti-PrP^C 6H4 (Prionics) antibody and developed with SuperSignal® West Dura (Pierce). (B) Western analysis of representative human CS F from control, 12 h within spinal cord injury and 7 d after spinal cord injury (40 µl). Four patients are shown. Blots were probed with anti-PrP^C 6H4 (Prionics) antibody or anti-PrP^C 11C6 antibody (SPI-BIO).

Figure 2 14-3-3 and IgG light chain levels in CS F after spinal cord injury. (A) Western analysis of 14-3-3 and IgG light chain after spinal cord injury. Three patients are shown. 14-3-3 is absent in all CS F samples. IgG light chains are present in varying amounts in all samples. 20 µg of rat brain supernatant and pellet fractions and 20 µg of PC12 cell homogenate (middle) are shown in the right lanes. (B) Western analysis of CS F (40 µl) after spinal cord injury for αA/αB crystallin and Hsp27.

Figure 3 Molecular chaperones were not detected in CSF of control or spinal cord injured patients. Western analysis of Hsp40, Rdj-2, Hdj-2, Hsp110, Hsp90, Hsc70, Hsp70 and Hsp60 in CS F samples (40 µl) from control or spinal cord injured patients as indicated. 20 µg of rat brain supernatant and pellet fractions are shown in the right lanes.

Table 1 Clinical characteristics of the patients included in the study

Patient	PrP^C Level	αA/αB-crystallin	Hsp27	Patient age	Patient sex	Motor recovery after 6 mo	Treatment
C1				29	M
C2				82	F
C3				46	M
C4		−		39	F
C7		−	+	69	F
C8		−	+	46	M
SCI 05-12 h	↓	+	+	54	M	27	Minocycline
SCI 05-day 7	↓	−	−
SCI 11–12 h	↓	−	+	33	F		Placebo
SCI 11-day 7	↓	+	−
SCI 13-12 h	↓	−	+	18	F	Total	Minocycline
SCI 13-day 7	↓	−	−
SCI 14-12 h	↓	ND	ND	21	M		Placebo
SCI 14-day 7	↓	ND	ND
SCI 15-12 h	↓	−	+	25	M	10	Minocycline
SCI 15-day 7	↓	−	−
SCI 16-12 h	↓	+	+	20	M	Deceased at 3 weeks	Minocycline
SCI 16-day 7	↓	−	−
SCI 18-12 h	↓	−	ND	31	M	0	Minocycline
SCI 18-day 7	↓	+	ND
SCI 19-12 h	↓	−	+	47	M	21	Placebo
SCI 19-day 7	↓	−	−
SCI 20-12 h	↓	−	−	39	F	13	Placebo
SCI 20-day 7	↓	+	+
SCI 22-12 h	↓	−	−	22	M	0	Placebo
SCI 22-day 7	↓	−	−
SCI 25-12 h	↓	−	+	43	M	47	Minocycline
SCI 25-day 7	↓	−	−
SCI 28-12 h	↓	+	+	16	F	0	Placebo
SCI 28-day 7	↓	−	−
SCI 31-12 h	↓	−	+	48	M	4	Placebo
SCI 31-day 7	↓	+	−

Symbols are: (↓) decreased compared to control. (+) present, (−) absent, (ND) not determined, (M) male, (F) female, Motor recovery scores: high for good recovery and low for poor recovery.